Search the Studies

25 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number Title Protocol Status Min-Max Age Institute Keywords
001733-CA Phase 1 Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal CarcinomaParticipants currently recruited/enrolled18-100 YearsNCI Adenocarcinoma
001583-CA Phase 1/2 Open-Label, Multicenter, Dose Escalation and Expansion Study of AVB-001, an Intraperitoneally Administered, Cell-Generated, Human IL-2 Immunotherapy in Patients With Platinum-Resistant, High-Grade, Serous Adenocarcinoma of the Ovary, Primary Completed Study; data analyses ongoing18-120 YearsNCI Adenocarcinoma
001552-CPhase II Study of Enasidenib in IDH2-mutated Malignant Sinonasal and Skull Base TumorsParticipants currently recruited/enrolled18-120 YearsNCI Adenocarcinoma
001535-CA Phase II Study of Sacituzumab Govitecan with or without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile CancerRecruitment has not started18-120 YearsNCI Adenocarcinoma
001533-CA Phase II Multicenter Study of Enfortumab Vedotin with or without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)Recruitment has not started18-120 YearsNCI Adenocarcinoma
001004-CA Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon Oncosignature(R) StatusParticipants currently recruited/enrolled18-120 YearsNCI Adenocarcinoma
000611-CA Phase II Trial of Focal Ultrahypofractionated Stereotactic Radiation Therapy for the Treatment of Unifocal Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI Adenocarcinoma
000302-CA Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract MalignanciesParticipants currently recruited/enrolled18-125 YearsNCI Adenocarcinoma
000254-CA Phase II Trial of the Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)Participants currently recruited/enrolled18-125 YearsNCI Adenocarcinoma
000194-CA Phase I Trial of ProAgio, an anti- alpha-v-beta3 Integrin Cytotoxin, for Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor MalignanciesParticipants currently recruited/enrolled18-120 YearsNCI Adenocarcinoma
20-C-0150Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation CarriersParticipants currently recruited/enrolled18-125 YearsNCI Adenocarcinoma
20-C-0149Phase II Trial of Olaparib (LYNPARZA) plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas that Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine TumorsParticipants currently recruited/enrolled18-125 YearsNCI Adenocarcinoma
19-C-0129A Phase II Study of Intraperitoneal and Intravenous Paclitaxel Chemotherapy with Oral Capecitabine for Gastric Adenocarcinoma with Peritoneal CarcinomatosisNo longer recruiting/follow-up only18-125 YearsNCI Adenocarcinoma
19-C-0128A Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination with Tofacitinib in Persons with Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and other Mesothelin Expressing Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Adenocarcinoma
19-C-0016Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid TumorsParticipants currently recruited/enrolled0-125 YearsNCI Adenocarcinoma
18-C-0143A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior ChemotherapyCompleted Study; data analyses ongoing18-125 YearsNCI Adenocarcinoma
18-C-0024A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy with Floxuridine and Dexamethasone in Combination with Systemic Chemotherapy for Patients with Colorectal Cancer Metastatic to the LiverParticipants currently recruited/enrolled18-125 YearsNCI Adenocarcinoma
17-C-0092A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal CancerCompleted Study; data analyses ongoing18-125 YearsNCI Adenocarcinoma
17-C-0070Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer with Positive Peritoneal CytologyNo longer recruiting/follow-up only18-125 YearsNCI Adenocarcinoma
17-C-0043Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric CancerParticipants currently recruited/enrolled2-125 YearsNCI Adenocarcinoma
16-C-0128A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Adenocarcinoma
16-C-0092A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib (AZD9291, Tagrisso)Completed Study; data analyses ongoing18-125 YearsNCI Adenocarcinoma
14-C-0104A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived from Patients with Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative RegimenParticipants currently recruited/enrolled18-72 YearsNCI Adenocarcinoma
09-C-0161Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch StudiesEnrolling by Invitation18-125 YearsNCI Adenocarcinoma
05-CC-0091Electromagnetic Tracking of Devices During Interventional ProceduresEnrolling by Invitation18-120 YearsCC Adenocarcinoma
10 Center Drive,Bethesda, MD 20892 | Directions
Privacy Statement | Accessibility | Plain Language | FOIA | Disclaimer
Clinical Center | National Institutes of Health | HHS Vulnerability Disclosure | U.S. Department of Health and Human Services | USA.gov
NIH…Turning Discovery Into Health®